Clinical mastitis in dairy cows: adding systemic to intramammary therapy — LIKELY

In dairy cows with clinical mastitis, does adding systemic therapy to intramammary treatment improve bacteriological cure compared with intramammary therapy alone?

Shelf #153 · gate-verified and approved by the developer

LIKELY: Adding systemic therapy to intramammary treatment has not been shown to improve bacteriological cure. The direct test — a Danish noninferiority randomised trial in mild to moderate clinical mastitis caused by gram-positive bacteria — found local penicillin alone noninferior to local plus systemic penicillin (unadjusted bacteriological cure 76.8% local vs 83.1% combined, against a prespecified 15% relative noninferiority margin), with a potential 16-fold reduction in antimicrobial use per case. Two further randomised add-on trials agree in direction: adding intramuscular ceftiofur to intramammary therapy in systemically mild clinical mastitis gave no benefit on loss of quarter, recurrence or culling (Wenz 2005), and adding systemic enrofloxacin in acute Escherichia coli mastitis did not increase bacteriological cure (90.5% treated vs 86.8% untreated). The one contrary signal is older and weaker: a 2003 comparison using non-randomised controls found combined parenteral-plus-intramammary treatment superior to parenteral treatment alone for penicillin-susceptible Staphylococcus aureus (75.6% vs 56.1% cure) — a systemic-alone comparator, not intramammary alone, and a pathogen where route questions may genuinely differ. This shelf's home is the route-of-therapy question; culture-guided selective vs blanket treatment is a different shelf (#152). Drafted Nov 10, 2026 (VetMed build, topic #153); all figures from abstracts fetched and verified at drafting.

Svennesen 2023: local penicillin alone was noninferior to local plus systemic penicillin for bacteriological cure of mild/moderate gram-positive clinical mastitis (76.8% vs 83.1%)

Noninferiority randomized trial (record's own title and publication types)

Who: Dairy cows: clinical mastitis cases from 12 Danish dairy farms; of 1,972 clinical mastitis cases registered, 345 (18%) met all criteria for inclusion in the full data set (265 cases in the multivariable analysis), restricted to mild and moderate cases with suspected gram-positive bacteria selected on-farm within 24 hours, allocated to local intramammary penicillin alone or combined local plus systemic penicillin.

Result: Streptococcus uberis was the most commonly isolated pathogen. Noninferiority was demonstrated for both unadjusted and adjusted cure rates, against a noninferiority margin set to a relative reduction in bacteriological cure of 15%. The unadjusted bacteriological cure rates were 76.8% for local treatment and 83.1% for combined treatment (full data). The authors concluded that bacteriological cure with local penicillin treatment was noninferior to combined local and systemic treatment, suggesting a potential 16-fold reduction in antimicrobial use per mastitis treatment with no adverse effect on cure rate. Pathogen and somatic cell count before the clinical case affected treatment efficacy similarly under both protocols.

Watch out: Gram-positive, mild to moderate cases only, selected by on-farm tests — the result does not cover severe mastitis or gram-negative cases, and the 15% relative noninferiority margin is generous: combined treatment's cure rate was numerically higher (83.1% vs 76.8%), and 'noninferior within 15% relative' is not 'identical'. Blinding is not stated in the record and is not claimed; allocation was by the treatment groups described in the record.

Svennesen L, Skarbye AP, Farre M, Astrup LB, Halasa T, Krömker V, Denwood M, Kirkeby C. Treatment of mild to moderate clinical bovine mastitis caused by gram-positive bacteria: A noninferiority randomized trial of local penicillin treatment alone or combined with systemic treatment. J Dairy Sci. 2023;106(8):5696-5714. PMID: 37331876. Registry ID: none in the record. MeSH: Cattle · Female · Animals · Mastitis, Bovine/drug therapy,microbiology · Anti-Bacterial Agents/therapeutic use,pharmacology · Gram-Positive Bacteria · Bacteria · Penicillins/therapeutic use · Milk · Cattle Diseases/drug therapy

Wenz 2005: adding intramuscular ceftiofur to intramammary therapy gave no benefit in systemically mild clinical mastitis

Randomized controlled trial (record's own publication types; abstract states cows were randomly assigned)

Who: Dairy cows: lactating dairy cattle with systemically mild clinical mastitis, randomly assigned to pirlimycin intramammary (n = 35), pirlimycin intramammary plus ceftiofur intramuscular (n = 36), cephapirin intramammary (n = 40), or cephapirin intramammary plus ceftiofur intramuscular (n = 33); 69% of initial cultures were gram-negative, 22% gram-positive and 9% mixed. Ceftiofur was given intramuscularly at 2.2 mg/kg.

Result: Logistic regression analysis showed no significant associations between treatment groups and loss of quarter, recurrence, or culling. Mixed infections, positive milk culture at 7 days after leaving the hospital pen, decreased rumen motility, and absence of udder firmness were associated with increased odds of mastitis recurrence. The authors concluded that intramuscular ceftiofur treatment has no beneficial effects on the outcome of systemically mild clinical mastitis.

Watch out: The record's abstract does not report bacteriological cure rates — its outcomes are loss of quarter, recurrence and culling — so this card supports the 'no added benefit' conclusion on clinical outcomes, not directly on cure. The abstract's group list prints one ceftiofur arm as 'i.m.m.' where the study objective and dose line make clear the ceftiofur was the parenteral (i.m.) add-on; the card follows the objective. Blinding is not stated in the record.

Wenz JR, Garry FB, Lombard JE, Elia R, Prentice D, Dinsmore RP. Short communication: Efficacy of parenteral ceftiofur for treatment of systemically mild clinical mastitis in dairy cattle. J Dairy Sci. 2005;88(10):3496-9. PMID: 16162523. Registry ID: none in the record. MeSH: Animals · Cattle · Cephalosporins/administration & dosage · Cephapirin/administration & dosage · Clindamycin/administration & dosage,analogs & derivatives · Female · Injections, Intramuscular · Lactation · Logistic Models · Mammary Glands, Animal/drug effects · Mastitis, Bovine/diagnosis,drug therapy · Recurrence

Sérieys 2005: systemic penethamate alone and intramammary ampicillin/cloxacillin alone did not differ in bacteriological or clinical cure

Open, randomized, controlled multicenter field trial (record's own wording)

Who: Dairy cows: lactating cows suffering from infectious clinical mastitis in one quarter, in an open, randomized, controlled multicenter field trial comparing intramuscular penethamate hydriodide over 3 consecutive days with intramammary ampicillin/cloxacillin combination, with clinical examinations on days 1, 3, 8, 17 and 22 and milk bacteriology on days 1, 17 and 22.

Result: There was no significant difference in bacteriological and clinical cure rates between the 2 treatment groups. Systemic treatment with penethamate more frequently reduced milk somatic cell count below the threshold of 250,000 cells/mL, including in adjacent quarters not affected by clinical mastitis but with a somatic cell count above 250,000 cells/mL before treatment, suggesting parenteral treatment provides collateral cure of subclinical mastitis in other quarters.

Watch out: This trial compares systemic alone against intramammary alone — it does not test the combination — and the abstract reports no cure-rate figures, only the absence of a significant difference, so no rates are quoted here. It was explicitly open (unblinded). Its collateral-cure finding cuts the other way for cows with several quarters affected: route choice may matter by number of quarters involved, as the authors themselves conclude.

Sérieys F, Raguet Y, Goby L, Schmidt H, Friton G. Comparative efficacy of local and systemic antibiotic treatment in lactating cows with clinical mastitis. J Dairy Sci. 2005;88(1):93-9. PMID: 15591371. Registry ID: none in the record. MeSH: Ampicillin/administration & dosage,therapeutic use · Animals · Cattle · Cell Count · Cloxacillin/administration & dosage,therapeutic use · Drug Therapy, Combination/administration & dosage,therapeutic use · Escherichia coli/isolation & purification · Female · Injections, Intramuscular · Lactation · Mammary Glands, Animal/drug effects · Mastitis, Bovine/drug therapy,microbiology · Milk/cytology,microbiology · Penicillin G/administration & dosage,analogs & derivatives,therapeutic use · Staphylococcus aureus/isolation & purification · Streptococcus/isolation & purification

Taponen 2003: combined parenteral plus intramammary treatment beat parenteral treatment alone for penicillin-susceptible Staph. aureus (75.6% vs 56.1% cure) — with non-randomised controls

Comparative study with non-randomised controls (record's own wording: controls 'used' from the same practice area; no randomisation stated)

Who: Dairy cows: cows with clinical mastitis caused by Staphylococcus aureus (166 mastitic quarters) treated during routine farm calls, given targeted 5-day combined parenteral and intramammary treatment based on in vitro susceptibility (procaine penicillin G for 86 beta-lactamase-negative cases; amoxycillin-clavulanic acid for 24 beta-lactamase-positive cases), compared with controls from the same practice area treated parenterally only (41 penicillin-susceptible cases with procaine penicillin G; 15 penicillin-resistant cases with spiramycin).

Result: Bacteriological cure rate after combination treatment was 75.6% for quarters infected with penicillin-susceptible S. aureus isolates and 29.2% for quarters infected with penicillin-resistant isolates. Cure rate for quarters treated only parenterally with procaine penicillin G was 56.1%, and for quarters treated with spiramycin 33.3%. Combined treatment was superior over systemic treatment only in the beta-lactamase negative group; the difference in cure rates between mastitis due to penicillin-susceptible and penicillin-resistant S. aureus was highly significant.

Watch out: The contrary card on this shelf, and the weakest design: the combined-treatment group was compared with separately assembled parenteral-only controls, with no randomisation stated in the record, and the comparator is systemic alone — not the intramammary-alone arm of this shelf's question. Its signal is confined to penicillin-susceptible S. aureus, where deep tissue infection makes route plausibly matter more; it does not overturn the randomised gram-positive noninferiority result, but it is why this shelf does not claim route never matters.

Taponen S, Jantunen A, Pyörälä E, Pyörälä S. Efficacy of targeted 5-day combined parenteral and intramammary treatment of clinical mastitis caused by penicillin-susceptible or penicillin-resistant Staphylococcus aureus. Acta Vet Scand. 2003;44(1-2):53-62. PMID: 14650544. Registry ID: none in the record. MeSH: Amoxicillin-Potassium Clavulanate Combination/administration & dosage,therapeutic use · Animals · Anti-Bacterial Agents/administration & dosage,therapeutic use · Cattle · Female · Mastitis, Bovine/drug therapy,microbiology · Milk/microbiology · Penicillin G Procaine/administration & dosage,therapeutic use · Penicillin Resistance · Staphylococcal Infections/drug therapy,veterinary · Staphylococcus aureus/drug effects,pathogenicity · Treatment Outcome · beta-Lactam Resistance

Suojala 2010: adding systemic enrofloxacin did not increase bacteriological cure in acute E. coli mastitis (90.5% vs 86.8%)

Randomised trial (record states cows were randomly allocated; publication types as indexed)

Who: Dairy cows: 132 dairy cows with naturally occurring acute clinical Escherichia coli mastitis and confirmed E. coli growth in a pretreatment milk sample, randomly allocated to systemic enrofloxacin (5 mg/kg twice at a 24-hour interval, first dose i.v., second s.c.) plus ketoprofen, or ketoprofen anti-inflammatory treatment only, with response evaluated clinically and bacteriologically on days 2 and 21 posttreatment.

Result: Enrofloxacin treatment did not increase bacteriological cure (90.5% of treated vs 86.8% of nontreated cured) or clinical cure (46.7% of treated vs 57.1% of nontreated cured), cow survival (95.3% of treated vs 92.7% of nontreated), or quarter milk production at 21 days, nor did it decrease mammary tissue damage estimated by milk NAGase activity, and it did not influence the number of cows remaining in the herd after 6 months (71.9% of treated vs 80.6% of nontreated). The only significant effects were on day 2: enhanced bacteriological cure (odds ratio = 3.32 for treated cows) and decreased clinical cure (odds ratio = 0.05 for treated cows). The authors concluded their results did not support the use of enrofloxacin to treat acute clinical E. coli mastitis.

Watch out: The add-on tested here is systemic antibiotic added to anti-inflammatory treatment — neither group received intramammary antibiotic — so this card answers the systemic add-on question for gram-negative (E. coli) mastitis by analogy, not the exact intramammary-plus-systemic comparison. Blinding is not stated in the record. The day-2 odds ratios move in opposite directions for bacteriological and clinical cure and had disappeared by day 21.

Suojala L, Simojoki H, Mustonen K, Kaartinen L, Pyörälä S. Efficacy of enrofloxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis. J Dairy Sci. 2010;93(5):1960-9. PMID: 20412909. Registry ID: none in the record. MeSH: Acetylglucosaminidase/metabolism · Animals · Anti-Infective Agents/therapeutic use · Anti-Inflammatory Agents, Non-Steroidal/therapeutic use · Cattle · Enrofloxacin · Escherichia coli Infections/drug therapy,veterinary · Female · Fluoroquinolones/pharmacology,therapeutic use · Ketoprofen/pharmacology,therapeutic use · Lactation/drug effects · Mastitis, Bovine/drug therapy · Milk/enzymology,metabolism,microbiology · Random Allocation · Treatment Outcome

Synthesis: three randomised add-on tests found no cure benefit from systemic therapy; the one positive signal is older, non-randomised, and Staph. aureus-specific

Synthesis

Who: Synthesis of the cards above: Svennesen 2023 (345 clinical mastitis cases, 12 Danish dairy farms, noninferiority randomised trial), Wenz 2005 (144 systemically mild cases, randomised), Sérieys 2005 (lactating cows, open randomised multicentre field trial), Taponen 2003 (166 S. aureus quarters plus non-randomised controls) and Suojala 2010 (132 acute E. coli cases, randomly allocated).

Result: For mild to moderate gram-positive clinical mastitis, intramammary penicillin alone was noninferior to intramammary plus systemic penicillin for bacteriological cure (76.8% vs 83.1%, within a 15% relative margin). Adding intramuscular ceftiofur to intramammary therapy did not improve loss of quarter, recurrence or culling, and adding systemic enrofloxacin in E. coli mastitis did not improve bacteriological cure (90.5% vs 86.8%). Systemic alone and intramammary alone did not differ in the one open head-to-head. The single study favouring combination therapy compared it against systemic treatment alone, used non-randomised controls, and was confined to penicillin-susceptible Staphylococcus aureus (75.6% vs 56.1%).

Watch out: Anchor correction versus the draft: the draft anchor named Schukken/Wenz programmes — the Wenz programme is genuine and carded (Wenz 2005), but no Schukken-programme randomised trial of the route question was found in this session's PubMed search; the Schukken-associated randomised work addresses culture-guided selective treatment, which is shelf #152's home, not this one. Severe (systemically ill) mastitis is barely represented here: Svennesen covers mild/moderate cases and Wenz systemically mild cases, so this shelf's answer should not be read onto toxic mastitis.

Synthesis of Svennesen L et al. PMID: 37331876; Wenz JR et al. PMID: 16162523; Sérieys F et al. PMID: 15591371; Taponen S et al. PMID: 14650544; Suojala L et al. PMID: 20412909. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.